This medicine is authorised for use in the European Union.


Humira is a medicine that acts on the immune system and is used to treat the following conditions:

  • plaque psoriasis, a disease causing red, scaly patches on the skin
  • psoriatic arthritis (red, scaly patches on the skin with inflammation of the joints)
  • rheumatoid arthritis (a disease causing inflammation of the joints)
  • axial spondyloarthritis (inflammation of spine causing back pain), including ankylosing spondylitis and when X-ray does not show disease but there are clear signs of inflammation
  • Crohn’s disease (a disease causing inflammation of the gut)
  • ulcerative colitis (a disease causing inflammation and ulcers in the lining of the gut)
  • polyarticular juvenile idiopathic arthritis and active enthesitis-related arthritis (both rare diseases causing inflammation in the joints)
  • hidradenitis suppurativa (acne inversa), a chronic skin disease that causes lumps, abscesses (collections of pus) and scarring on the skin
  • non-infectious uveitis (inflammation of the layer beneath the white of the eyeball).

Humira is mostly used in adults when their conditions are severe, moderately severe or getting worse, or when patients cannot use other treatments. For detailed information on the use of Humira in all conditions, including when it can be used in children, see package leaflet or contact your doctor or pharmacist.

Humira contains the active substance adalimumab.

This EPAR was last updated on 16/12/2022

Authorisation details

Product details
Agency product number
Active substance
International non-proprietary name (INN) or common name
Therapeutic area (MeSH)
  • Spondylitis, Ankylosing
  • Arthritis, Juvenile Rheumatoid
  • Uveitis
  • Colitis, Ulcerative
  • Psoriasis
  • Arthritis, Psoriatic
  • Crohn Disease
  • Arthritis, Rheumatoid
Anatomical therapeutic chemical (ATC) code
Publication details
Marketing-authorisation holder
AbbVie Deutschland GmbH Co. KG
Date of issue of marketing authorisation valid throughout the European Union
Contact address

67061 Ludwigshafen

Product information

10/10/2022 Humira - EMEA/H/C/000481 - IB/0213

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group


Therapeutic indication

Please refer to the product information document.

Assessment history

Changes since initial authorisation of medicine


Related content

How useful was this page?

Add your rating
2 ratings
1 rating
2 ratings
10 ratings